pharma
publication date
Finance
HHS Proposal Could Kill PBM Rebates: Some Pleased, Others Concerned
The proposal would end safe-harbor protections for the rebates drug manufacturers pay to PBMs and add safe-harbor protections for drug...
Strategy
Walgreens-Microsoft Alliance Puts More Pressure on Hospitals
The drugstore chain's partnership with Microsoft is designed to close existing gaps in care in the traditional healthcare system, says...
Finance
Secretive 'Rebate Trap' Keeps Generic Drugs For Diabetes And Other Ills Out Of Reach
Drug companies routinely make hidden pacts with middlemen that effectively block patients from getting cheaper generic medicines.
Finance
Azar Defends Plan to Lower Part B Drug Costs
Drugmakers aren't just going to walk away from Medicare, he says.
Clinical Care
Top Cancer Doctor, Forced Out Over Ties to Drug Makers, Joins Their Ranks
AstraZeneca has hired Dr. José Baselga, the former chief medical officer at Memorial Sloan Kettering, to lead its cancer research...
Finance
Why The U.S. Remains The World's Most Expensive Market For 'Biologic' Drugs
Biologic drugs, made from living organisms, are big moneymakers partly because they have little competition from 'biosimilars.' It's a very...
Strategy
Cigna–Express Scripts Secures Final Regulatory Approval
The $71 billion deal, which joins a major insurer with a PBM, is expected to close Thursday.
Clinical Care
Prominent Doctors Aren't Disclosing Their Industry Ties in Medical Journal Studies. And Journals Are Doing Little to Enforce Their Rules
The dean of Yale's medical school, the incoming president of a prominent cancer group and the head of a Texas...
340B Final Rule Will Launch on January 1, 2019
HHS shortens the 340B final rule implantation by six months after determining that it would not 'interfere' with the departments...
Strategy
'We Will Go Further': Azar Eyes Mandate Despite PhRMA's New Approach to TV Ads
The HHS secretary called PhRMA's voluntary action 'a small step in the right direction' but vowed to carry the Trump...
Strategy
In The Battle To Control Drug Costs, Old Patent Laws Get New Life
The strategies involve repurposing two obscure and rarely deployed workarounds in patent law. These ideas also are finding traction among...
Drugmakers Play The Patent Game To Lock In Prices, Block Competitors
The patenting of a small change in how an existing drug is made or taken by patients is part of...